Saruparib

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameSaruparib
Drug Alias NameAZD-5305AZD5305
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcNational Cancer InstituteAstrazeneca Ab +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A